APVO News and Press, Aptevo Therapeutics Inc. From 10/08/19

Several days ago, Aptevo Therapeutics ( APVO ) provided a corporate and pipeline update that surprised me (and I don't get surprised easily). To begin with, the company's hemophilia B drug IXINITY will do about $9M in revenue for Q3'19. This is a very important milestone for the company,...

Reports Record Quarterly IXINITY ® Net Revenue and New Patient Conversions  Following Launch of New 3,000 IU Assay Provides Update on Ongoing APVO436 Phase 1/1b Clinical Study; Evidence of Potential Clinical Activity Emerging; No Dose-Limiting Toxicities or Anti-drug An...

New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific Antibody Targeting 4-1BB and OX40 APVO603 is Designed to Induce Synergistic Effects on Immune Responses with Potential to Enhance Anti-Tumor Immune Response Against Solid Tumors SEATTLE, Sept. 19, 2019 (GLOBE NEWSWIRE)...

As I said in the previous article on the company, my metric for Aptevo Therapeutics ( APVO ) having a good Q2'19 quarter was even a slight increase in IXINITY revenue (the company's commercial Hemophilia B drug). The company reported IXINITY revenue of $7.4 million, which was up by $0.4M s...

Aptevo Therapeutics (NASDAQ: APVO ): Q2 GAAP EPS of -$0.30 misses by $0.04 . More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

Reports Positive Preliminary Top-Line Safety Data for APVO210 Phase 1 Single Ascending Dose (SAD) Clinical Study Advances APVO210 into Phase 1 Multiple Ascending Dose (MAD) Study Commences Dosing in Cohort 4 of APVO436 Phase 1 AML/MDS Clinical Trial Achieves 32% Increase in ...

SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the receipt of a $4.3 million milestone payment from Saol International Limited (Saol). This performa...

While there is not much in terms of headline news for Aptevo Therapeutics ( APVO ) as of late, there are many things happening "under the hood" that might warrant investor's attention. Because depending on how things proceed for the company, the profits to be had for investors might be extra...

Completes Dosing in Single Ascending Dose (SAD) Phase 1 Study of APVO210 Receives Approval to Begin APVO210 Multiple Ascending Dose (MAD) Study Preliminary Data Suggest that Single Doses of APVO210 Appear to be Safe and Well Tolerated at Doses Equivalent to IL-10 Doses that Genera...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...